"Sept. 26, 2014 -- Spotting cancer early is key, but trying to do that -- often when there are no symptoms -- has been challenging.
Still, more and more evidence suggests that all cancers have a sign"...
Mesnex Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Mesnex (mesna) is used to prevent bleeding in the bladder (hemorrhagic cystitis) during chemotherapy with ifosfamide (Ifex). It is detoxifying agent. Some forms of this medication are available in generic form. Common side effects include headache, flushing, dizziness, drowsiness, nausea, vomiting, loss of appetite, diarrhea, constipation, sensitive skin, or flu-like symptoms (e.g., sore throat, fever, chills, shivering, cough, body aches).
The dose of Mesnex is determined by the dose of ifosfamide being given. It is unknown if other medicines will interact with Mesnex. Tell your doctor all prescription or over-the-counter medicines and supplements you use. During pregnancy, Mesnex should be used only when prescribed. It is unknown if this drug passes into breast milk. Since this medication is given with a cancer chemotherapy drug, breast-feeding while using Mesnex is not recommended. Consult your doctor before breast-feeding.
Our Mesnex (mesna) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Mesnex in Detail - Patient Information: Side Effects
Seek emergency medical attention or contact your healthcare provider immediately if you experience any of the following serious side effects:
- an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); or
- pink or red colored urine.
Other less serious side effects may be more likely to occur. Continue to take mesna, and contact your doctor if you experience any of the following side effects:
- nausea or vomiting;
- decreased appetite;
- stomach pain;
- sensitive skin or skin rash;
- paleness of the skin;
- coughing or cold symptoms;
- pain, redness, or irritation at the injection site;
- swelling or water retention; or
- low blood pressure.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Mesnex (Mesna)
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Mesnex Overview - Patient Information: Side Effects
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor immediately if any of these unlikely but serious side effects occur: chest pain, fast heartbeat, swelling ankles/feet, muscle weakness.
A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Mesnex (Mesna)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Mesnex FDA Prescribing Information: Side Effects
The following are discussed in more detail in other sections of the labeling.
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS
- Dermatological Toxicity [see WARNINGS AND PRECAUTIONS]
- Benzyl Alcohol Toxicity[see WARNINGS AND PRECAUTIONS]
- Laboratory Test Interferences [see WARNINGS AND PRECAUTIONS]
- Use in Patients with a History of Adverse Reactions to Thiol Compounds [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
MESNEX adverse reaction data are available from four Phase 1 studies in which single intravenous doses of 600-1200 mg MESNEX Injection without concurrent chemotherapy were administered to a total of 53 healthy volunteers and single oral doses of 600-2400 mg of MESNEX Tablets were administered to a total of 82 healthy volunteers. The most frequently reported side effects (observed in two or more healthy volunteers) for healthy volunteers receiving single doses of MESNEX Injection alone were headache, injection site reactions, flushing, dizziness, nausea, vomiting, somnolence, diarrhea, anorexia, fever, pharyngitis, hyperesthesia, influenza-like symptoms, and coughing. In two Phase 1 multiple-dose studies where healthy volunteers received MESNEX Tablets alone or intravenous MESNEX followed by repeated doses of MESNEX Tablets, flatulence and rhinitis were reported. In addition, constipation was reported by healthy volunteers who had received repeated doses of intravenous MESNEX.
Additional adverse reactions in healthy volunteers receiving MESNEX alone included injection site reactions, abdominal pain/colic, epigastric pain/burning, mucosal irritation, lightheadedness, back pain, arthralgia, myalgia, conjunctivitis, nasal congestion, rigors, paresthesia, photophobia, fatigue, lymphadenopathy, extremity pain, malaise, chest pain, dysuria, pleuritic pain, dry mouth, dyspnea, and hyperhidrosis. In healthy volunteers, MESNEX was commonly associated with a rapid (within 24 hours) decrease in lymphocyte count, which was generally reversible within one week of administration.
Because MESNEX is used in combination with ifosfamide or ifosfamide-containing chemotherapy regimens, it is difficult to distinguish the adverse reactions which may be due to MESNEX from those caused by the concomitantly administered cytotoxic agents.
Adverse reactions reasonably associated with MESNEX administered intravenously and orally in four controlled studies in which patients received ifosfamide or ifosfamide-containing regimens are presented in Table 3.
Table 3: Adverse Reactions in ≥ 5% of
Patients Receiving MESNEX in combination with Ifosfamide-containing Regimens
|N exposed||119 (100.0%)||119 (100%)|
|Incidence of AEs||101 (84.9%)||106 (89.1%)|
|Nausea||65 (54.6)||64 (53.8)|
|Vomiting||35 (29.4)||45 (37.8)|
|Constipation||28 (23.5)||21 (17.6)|
|Leukopenia||25 (21.0)||21 (17.6)|
|Fatigue||24 (20.2)||24 (20.2)|
|Fever||24 (20.2)||18 (15.1)|
|Anorexia||21 (17.6)||19 (16.0)|
|Thrombocytop eni a||21 (17.6)||16 (13.4)|
|Anemia||20 (16.8)||21 (17.6)|
|Granul ocytopenia||16 (13.4)||15 (12.6)|
|Asthenia||15 (12.6)||21 (17.6)|
|Abdominal Pain||14 (11.8)||18 (15.1)|
|Alopecia||12 (10.1)||13 (10.9)|
|Dyspnea||11 (9.2)||11 (9.2)|
|Chest Pain||10 (8.4)||11 (9.2)|
|Hypokalemia||10 (8.4)||11 (9.2)|
|Diarrhea||9 (7.6)||17 (14.3)|
|Dizziness||9 (7.6)||5 (4.2)|
|Headache||9 (7.6)||13 (10.9)|
|Pain||9 (7.6)||10 (8.4)|
|Sweating Increased||9 (7.6)||2 (1.7)|
|Back Pain||8 (6.7)||6 (5.0)|
|Hematuria||8 (6.7)||7 (5.9)|
|Injection Site Reaction||8 (6.7)||10 (8.4)|
|Edema||8 (6.7)||9 (7.6)|
|Edema Peripheral||8 (6.7)||8 (6.7)|
|Somnolence||8 (6.7)||12 (10.1)|
|Anxiety||7 (5.9)||4 (3.4)|
|Confusion||7 (5.9)||6 (5.0)|
|Face Edema||6 (5.0)||5 (4.2)|
|Insomnia||6 (5.0)||11 (9.2)|
|Coughing||5 (4.2)||10 (8.4)|
|Dyspepsia||4 (3.4)||6 (5.0)|
|Hypotension||4 (3.4)||6 (5.0)|
|Pallor||4 (3.4)||6 (5.0)|
|Dehydration||3 (2.5)||7 (5.9)|
|Pneumonia||2 (1.7)||8 (6.7)|
|Tachycardia||1 (0.8)||7 (5.9)|
|Flushing||1 (0.8)||6 (5.0)|
|1Intravenous dosing of ifosfamide and MESNEX followed by either intravenous or oral doses of MESNEX according to the applicable dosage schedule. [see DOSAGE AND ADMINISTRATION].|
The following adverse reactions have been reported in the postmarketing experience of patients receiving MESNEX in combination with ifosfamide or similar drugs, making it difficult to distinguish the adverse reactions which may be due to MESNEX from those caused by the concomitantly administered cytotoxic agents. Because these reactions are reported from a population of unknown size, precise estimates of frequency cannot be made.
Nervous System: Convulsion
Read the entire FDA prescribing information for Mesnex (Mesna)
Additional Mesnex Information
Mesnex - User Reviews
Mesnex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get the latest treatment options.